Araverus
NewsMarketsResearch
News
HeadlinesThreadsAtlas
© 2026 Araverus
AboutContactPrivacyTerms

Araverus does not provide financial, investment, or trading advice. All content is for informational purposes only. Full disclaimer

  1. News
  2. /
  3. Markets
  4. /
  5. Earnings

GE HealthCare's Q4 Revenue Jumps 7.1%, But Profitability Slips Amid Macro Headwinds

Araverus Team|Wednesday, February 4, 2026 at 11:46 AM

GE HealthCare's Q4 Revenue Jumps 7.1%, But Profitability Slips Amid Macro Headwinds

Araverus Team

Feb 4, 2026 · 11:46 AM

Earnings Report · GE HealthCare · Healthcare Technology · Profit Decline

Earnings ReportGE HealthCareHealthcare TechnologyProfit Decline

GE HealthCare Technologies reported a revenue growth of 7.1% in the fourth quarter, but the net income margin and earnings per share indicate a decline in profit, aligning with the challenges noted by CEO Peter Arduini in a dynamic macroeconomic environment.

Read More On

GE HealthCare Technologies Posts Lower Profit, Despite Higher Revenuewsj.comGE HealthCare reports fourth quarter and full year 2025 financial results - Yahoo! Finance Canadaca.finance.yahoo.com

Related Articles

Markets★★Similarity: 68% · 76d ago

Teradyne Profit Rises as Sales Surge on AI-Related Demand

The company, which makes testing equipment for semiconductors and robotics, posted a fourth-quarter profit of $257.2 million, up from $146.3 million a year earlier.

Markets★★Similarity: 68% · 74d ago

Boston Scientific Profit, Sales Rise but Issues Soft Guidance

Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.

Markets★★Similarity: 67% · 80d ago

Norfolk Southern Profit, Revenue Falls

Norfolk Southern reported lower income and revenue in the fourth quarter, as it continues to operate in what Chief Executive Mark George called a volatile and challenging macroeconomic environment.

Markets★★Similarity: 66% · 72d ago

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.